Journal · Updated 2026-08-11
Amble Health Review 2026: A $300 Tirzepatide-Only Row, Read Plainly
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Our record is one line: compounded tirzepatide at three hundred dollars a month, provider-stated, no semaglutide offering — and this review declines to pad it. Placement: a hundred-twenty-plus over the flat tier, one under OrderlyMeds' identical-altitude figure, inside the band where the approved product's two ninety-nine starter rung and four forty-nine maintenance vial frame every decision. What would fill the row: the pharmacy name, the inclusions, dose-flatness, exit terms — the standard four, in writing — plus the checkout capture our file has a blank for.
Reading a thin row, and verdict
A short public record cuts both ways: it can mean a small careful operator without a marketing engine, or a shallow one — and the difference lives entirely in the intake answers, which is why the four questions above are the review's substance. The buyer math meanwhile doesn't wait: at three hundred, tirzepatide-only, without an itemized bundle, Amble asks a hundred-twenty-plus monthly premium over programs whose rows are full — and in this market, the fullness of the row is part of the product. Verdict: a candidate for the buyer with a specific reason to prefer it who completes the verification personally; the default path runs through programs whose facts arrive before the card number does.
Questions people ask
How much is Amble Health?
$300/month for compounded tirzepatide, provider-stated — our record's single fact. No semaglutide offering appears; no bundle is itemized.
Is Amble Health legit?
Unresolved by public record — which is itself the finding: the standard verification (pharmacy name, license lookups, COA, terms in writing) is load-bearing here, and a program at a $120+ premium over the flat tier should make clearing it easy. If intake resists the questions, the market is full of rows that don't.
Amble vs the $169–$179 tirzepatide tier?
$121–$131/month premium with no itemized service case in our records — the arithmetic favors the flat tier absent specific answers. At $300, the approved product's $299 starter rung is also literally at parity for the first titration month.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.